First Trust Advisors L.P. > First Trust Exchange-Traded Fund
First Trust NYSE Arca Biotechnology Index Fund
$1.38B
Avg Monthly Net Assets
$1.11B
Total Assets
$765K
Total Liabilities
$1.11B
Net Assets
First Trust NYSE Arca Biotechnology Index Fund is an Exchange-Traded Fund in First Trust Exchange-Traded Fund
from First Trust Advisors L.P.,
based in Illinois,
United States of America.
The fund has one share class
and monthly net assets of $1.38B.
On August 21st, 2024 it reported 31 holdings, the largest
being Alnylam Pharmaceuticals Inc (5.2%), Corcept Therapeutics Inc (4.4%) and United Therapeutics Corp (4.4%).
Data provided by Fincoded.
Share Classes
| Name | Class/Contract ID | Exchange | Ticker | Monthly Returns (2 years) |
|---|---|---|---|---|
| First Trust NYSE Arca Biotechnology Index Fund | C000033929 | ARCX | FBT |
Holdings
From latest NPORT-P, filed August 21st, 2024 for period ending June 30th, 2024.
Historic holdings data available from Fincoded.
| Name | Profile | Category | Country | Value $USD | # Shares | % of Fund |
|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc | Long | Equity-common | US | $33M | 2M | 3.01 |
| Alkermes PLC | Long | Equity-common | IE | $35M | 1M | 3.14 |
| Alnylam Pharmaceuticals Inc | Long | Equity-common | US | $58M | 237K | 5.20 |
| Amgen Inc | Long | Equity-common | US | $41M | 132K | 3.71 |
| Argenx SE | Long | Equity-common | NL | $40M | 93K | 3.61 |
| Beam Therapeutics Inc | Long | Equity-common | US | $32M | 1M | 2.87 |
| BeiGene Ltd | Long | Equity-common | US | $36M | 249K | 3.21 |
| Biogen Inc | Long | Equity-common | US | $41M | 178K | 3.72 |
| BioMarin Pharmaceutical Inc | Long | Equity-common | US | $31M | 382K | 2.84 |
| BioNTech SE | Long | Equity-common | DE | $33M | 407K | 2.95 |
| Bruker Corp | Long | Equity-common | US | $26M | 402K | 2.31 |
| Catalyst Pharmaceuticals Inc | Long | Equity-common | US | $36M | 2M | 3.23 |
| Corcept Therapeutics Inc | Long | Equity-common | US | $49M | 1M | 4.39 |
| Dreyfus Government Cash Management | Long | Short-term investment vehicle | US | $726K | 726K | 0.07 |
| Exact Sciences Corp | Long | Equity-common | US | $21M | 494K | 1.88 |
| Exelixis Inc | Long | Equity-common | US | $35M | 2M | 3.13 |
| Genmab A/S | Long | Equity-common | DK | $30M | 1M | 2.73 |
| Gilead Sciences Inc | Long | Equity-common | US | $35M | 517K | 3.20 |
| Halozyme Therapeutics Inc | Long | Equity-common | US | $48M | 912K | 4.31 |
| Illumina Inc | Long | Equity-common | US | $30M | 284K | 2.68 |
| Incyte Corp | Long | Equity-common | US | $40M | 654K | 3.58 |
| Intra-Cellular Therapies Inc | Long | Equity-common | US | $37M | 534K | 3.30 |
| Mettler-Toledo International Inc | Long | Equity-common | US | $39M | 28K | 3.52 |
| Moderna Inc | Long | Equity-common | US | $40M | 335K | 3.59 |
| Natera Inc | Long | Equity-common | US | $40M | 373K | 3.64 |
| Neurocrine Biosciences Inc | Long | Equity-common | US | $36M | 261K | 3.25 |
| Regeneron Pharmaceuticals Inc | Long | Equity-common | US | $41M | 39K | 3.69 |
| Repligen Corp | Long | Equity-common | US | $26M | 205K | 2.33 |
| United Therapeutics Corp | Long | Equity-common | US | $48M | 151K | 4.35 |
| Vertex Pharmaceuticals Inc | Long | Equity-common | US | $42M | 89K | 3.76 |
| Waters Corp | Long | Equity-common | US | $32M | 109K | 2.86 |
Address
First Trust Exchange-Traded Fund
120 East Liberty Drive
Suite 400
Wheaton
Illinois
60187
United States of America
Websites
Directors
Robert F. Keith
Niel B. Nielson
Richard E. Erickson
Denise M. Keefe
Thomas R. Kadlec
James A. Bowen
Transfer Agents
The Bank of New York Mellon
Pricing Services
ICE Data Pricing & Reference Data, LLC
LSEG Pricing Service
Bloomberg L.P.
Custodians
The Bank of New York Mellon
Shareholder Servicing Agents
The Bank of New York Mellon
Admins
The Bank of New York Mellon
Brokers
Wolverine Execution Services LLC
X-CHANGE FINANCIAL ACCESS, LLC